Literature DB >> 18651699

CD11c: not merely a murine DC marker, but also a useful vaccination target.

Christian Kurts1.   

Abstract

The induction of robust CD4(+) and CD8(+) T cell responses is a central aim in antiviral and anticancer vaccination. To this end, dendritic cells (DC) need to capture the vaccine, process and present it on MHC class I and II molecules. The mechanisms by which DC acquire antigen predetermine the quantity and quality of the ensuing T cell activation. In this issue of the European Journal of Immunology, it is demonstrated that targeting antigen towards CD11c, an integrin expressed preferentially by murine DC, facilitates efficient CD4(+) and CD8(+) T cell activation. The underlying mechanisms involve efficient antigen delivery into the marginal zone and T/DC zone of the spleen. This commentary discusses these findings in the context of current knowledge on antigen presentation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18651699     DOI: 10.1002/eji.200838645

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

1.  Expression of MIP-1alpha (CCL3) by a recombinant rabies virus enhances its immunogenicity by inducing innate immunity and recruiting dendritic cells and B cells.

Authors:  Ling Zhao; Harufusa Toriumi; Hualei Wang; Yi Kuang; Xiaofeng Guo; Kinjiro Morimoto; Zhen F Fu
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

2.  DC targeting DNA vaccines induce protective and therapeutic antitumor immunity in mice.

Authors:  Qun Wang; Wei Cao; Zhi-Gang Yang; Guang-Fa Zhao
Journal:  Int J Clin Exp Med       Date:  2015-10-15

3.  Targeting viral antigens to CD11c on dendritic cells induces retrovirus-specific T cell responses.

Authors:  Asim Ejaz; Christoph G Ammann; Roland Werner; Georg Huber; Verena Oberhauser; Susanne Hörl; Simone Schimmer; Ulf Dittmer; Dorothee von Laer; Heribert Stoiber; Zoltán Bánki
Journal:  PLoS One       Date:  2012-09-17       Impact factor: 3.240

4.  A Universal Influenza Vaccine Can Lead to Disease Exacerbation or Viral Control Depending on Delivery Strategies.

Authors:  Cindy Bernelin-Cottet; Charlotte Deloizy; Ondrej Stanek; Céline Barc; Edwige Bouguyon; Céline Urien; Olivier Boulesteix; Jérémy Pezant; Charles-Adrien Richard; Mohammed Moudjou; Bruno Da Costa; Luc Jouneau; Christophe Chevalier; Claude Leclerc; Peter Sebo; Nicolas Bertho; Isabelle Schwartz-Cornil
Journal:  Front Immunol       Date:  2016-12-26       Impact factor: 7.561

5.  The HPV16 E7 Oncoprotein Disrupts Dendritic Cell Function and Induces the Systemic Expansion of CD11b(+)Gr1(+) Cells in a Transgenic Mouse Model.

Authors:  Gabriela Damian-Morales; Nicolás Serafín-Higuera; Mario Adán Moreno-Eutimio; Enoc M Cortés-Malagón; José Bonilla-Delgado; Genaro Rodríguez-Uribe; Rodolfo Ocadiz-Delgado; Paul F Lambert; Patricio Gariglio
Journal:  Biomed Res Int       Date:  2016-07-11       Impact factor: 3.411

6.  A DNA-Modified Live Vaccine Prime-Boost Strategy Broadens the T-Cell Response and Enhances the Antibody Response against the Porcine Reproductive and Respiratory Syndrome Virus.

Authors:  Cindy Bernelin-Cottet; Céline Urien; Elisabeth Stubsrud; Virginie Jakob; Edwige Bouguyon; Elise Bordet; Céline Barc; Olivier Boulesteix; Vanessa Contreras; Christophe Barnier-Quer; Nicolas Collin; Ivan Trus; Hans Nauwynck; Nicolas Bertho; Isabelle Schwartz-Cornil
Journal:  Viruses       Date:  2019-06-14       Impact factor: 5.048

7.  CD11c controls herpes simplex virus 1 responses to limit virus replication during primary infection.

Authors:  Sariah J Allen; Kevin R Mott; Aziz A Chentoufi; Lbachir BenMohamed; Steven L Wechsler; Christie M Ballantyne; Homayon Ghiasi
Journal:  J Virol       Date:  2011-07-20       Impact factor: 5.103

8.  Carbon nanotubes' surface chemistry determines their potency as vaccine nanocarriers in vitro and in vivo.

Authors:  Hatem A F M Hassan; Lesley Smyth; Noelia Rubio; Kulachelvy Ratnasothy; Julie T-W Wang; Sukhvinder S Bansal; Huw D Summers; Sandra S Diebold; Giovanna Lombardi; Khuloud T Al-Jamal
Journal:  J Control Release       Date:  2016-01-21       Impact factor: 9.776

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.